JP2022534420A - 眼のタンパク質凝集疾患を治療するための薬剤 - Google Patents

眼のタンパク質凝集疾患を治療するための薬剤 Download PDF

Info

Publication number
JP2022534420A
JP2022534420A JP2021570895A JP2021570895A JP2022534420A JP 2022534420 A JP2022534420 A JP 2022534420A JP 2021570895 A JP2021570895 A JP 2021570895A JP 2021570895 A JP2021570895 A JP 2021570895A JP 2022534420 A JP2022534420 A JP 2022534420A
Authority
JP
Japan
Prior art keywords
alkyl
cap4349
hydrogen
acid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021570895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534420A5 (https=
Inventor
プラサド，スリドハー・ゴビンダ
ピーターマン，マーシャル・クラーク
シンハ，サントシュ
Original Assignee
プレックス ファーマスーティカルズ，インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレックス ファーマスーティカルズ，インク filed Critical プレックス ファーマスーティカルズ，インク
Publication of JP2022534420A publication Critical patent/JP2022534420A/ja
Publication of JP2022534420A5 publication Critical patent/JP2022534420A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021570895A 2019-05-31 2020-06-01 眼のタンパク質凝集疾患を治療するための薬剤 Pending JP2022534420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855560P 2019-05-31 2019-05-31
US62/855,560 2019-05-31
PCT/US2020/035592 WO2020243720A1 (en) 2019-05-31 2020-06-01 Pharmacological agents for treating protein aggregation diseases of the eye

Publications (2)

Publication Number Publication Date
JP2022534420A true JP2022534420A (ja) 2022-07-29
JP2022534420A5 JP2022534420A5 (https=) 2023-06-09

Family

ID=73553335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570895A Pending JP2022534420A (ja) 2019-05-31 2020-06-01 眼のタンパク質凝集疾患を治療するための薬剤

Country Status (8)

Country Link
US (1) US20220241247A1 (https=)
EP (1) EP3976017A4 (https=)
JP (1) JP2022534420A (https=)
CN (1) CN114173771A (https=)
BR (1) BR112021024151A2 (https=)
CA (1) CA3141998A1 (https=)
MX (1) MX2021014682A (https=)
WO (1) WO2020243720A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4097092A1 (en) * 2020-01-28 2022-12-07 Protego Biopharma, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US20250019352A1 (en) * 2021-06-29 2025-01-16 Plex Pharmaceuticals, Inc. Pharmacological agents for treating ophthalmic diseases
WO2023009585A2 (en) * 2021-07-28 2023-02-02 Protego Biopharma, Inc. Transthyretin stabilizing compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530842A (ja) * 2011-10-24 2014-11-20 ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． トランスサイレチン関連アミロイドーシスの新規療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113523A1 (en) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
RU2586330C2 (ru) * 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
US9499527B2 (en) * 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US9790269B2 (en) * 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
RU2015138891A (ru) * 2013-03-08 2017-04-11 Аллерган, Инк. Конъюгаты антибиотиков, напрямую связанные со стероидными препаратами
PE20151747A1 (es) * 2013-03-14 2015-12-18 Univ Massachusetts Metodo para inhibir cataratas y presbicia
US11872236B2 (en) * 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530842A (ja) * 2011-10-24 2014-11-20 ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． トランスサイレチン関連アミロイドーシスの新規療法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEIRAO, M. ET AL., AMYLOID, vol. 18, no. 3, JPN6024021082, 2011, pages 92 - 97, ISSN: 0005466871 *
SUGIOKA, K. ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 488, no. 3, JPN6024021083, 2017, pages 483 - 488, ISSN: 0005466870 *

Also Published As

Publication number Publication date
CN114173771A (zh) 2022-03-11
US20220241247A1 (en) 2022-08-04
CA3141998A1 (en) 2020-12-03
BR112021024151A2 (pt) 2022-02-08
MX2021014682A (es) 2022-04-06
WO2020243720A9 (en) 2021-02-04
WO2020243720A1 (en) 2020-12-03
EP3976017A4 (en) 2023-06-14
EP3976017A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
JP7457401B2 (ja) 毒性アルデヒド関連疾患および処置
JP5743326B2 (ja) サーチュインモジュレーターとしてのクロメノンアナログ
JP5628828B2 (ja) チアゾロピリジンサーチュイン調節化合物
JP2021008473A (ja) 細胞生存率を向上させるための組成物およびその使用方法
JP2019532029A (ja) アルデヒド補足化合物およびその使用
US20110256064A1 (en) Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
CA3032609A1 (en) Aldehyde trapping compounds and methods of use thereof
JP4234430B2 (ja) チオールを含むｎａａｌａｄアーゼ抑制物質
EA021938B1 (ru) Хинолины и их аналоги в качестве модуляторов сиртуина
JP2022534420A (ja) 眼のタンパク質凝集疾患を治療するための薬剤
GB2144993A (en) Ophthalmic anti-inflammatory agents
JPWO1999033818A1 (ja) ビタミンｅ誘導体
KR20220127826A (ko) 화합물 및 α1-항트립신 결핍의 치료를 위한 이의 용도
WO2007037188A1 (ja) 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
WO2020213693A1 (ja) リポ酸プロドラッグ
US20180353482A1 (en) Mirabegron for the treatment of retinal diseases
WO2016068278A1 (ja) 水晶体硬化抑制剤
US20200276211A1 (en) Compounds for treating near vision disorders
US20070054901A1 (en) Dihydrothiazine prodrugs of thiazolium agents
JP3496111B2 (ja) 涙液分泌促進および角結膜障害治療剤
JP7158466B2 (ja) てんかん、神経変性疾患、及び他のｃｎｓ疾患を治療するための化合物
TW202330510A (zh) 對老花眼等之治療或預防有用之含硫化合物
JPH06500328A (ja) ５―リポキシゲナーゼインヒビターとしてのフェノール性チオエーテルアミド
KR20250051358A (ko) 항노화용 조성물
HK40123243A (zh) 用甘氨酸转运抑制剂治疗肝性卟啉症的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241122